Ladies and gentlemen, thank you for standing by, and welcome to the Erytech's Second Quarter 2019 Conference Call. [Operator Instructions] I would now like to hand the conference over to your speaker today, Gil Beyen, Chief Executive Officer. Please go ahead, sir.
Thank you, Shannon. Good morning and good afternoon to all. Thanks for joining our Second Quarter First Half 2019 earnings call. We announced our Q2 financial results and business update yesterday evening. You have seen the press release most likely. If not, you can access it on our website. Also, this -- the presentation is on our website on the Investor section.
Here with me in Lyon are Dr. Iman El-Hariry, our Chief Medical Officer and Eric Soyer, our Chief Financial and our Chief Operating Officer. So let's get started. I draw your attention to the disclaimer on Slide 2 and then switch to the agenda on Page 3. So it's our quarterly routine.
Following our quarterly routine, I will start with providing the business update and focus on the key highlights for the second quarter and the year-to-date. Eric will then take over to present the financial highlights for the first half of the year, and he will also summarize the major expected milestones for the remaining 12 months or the coming 12 months. We will all be -- then be available to respond to your questions.
So -- and before starting the update, I think it's always a good practice to remind the essentials of our Company. They are summarized on Slide 4. You can see, and not surprisingly, the same profile as at our last update call. We are still the Red Cell Company focused on cancer metabolism with [Indecipherable] as the core, late stage trials in pancreatic cancer Phase III; triple-negative breast cancer, Phase II; and an IST in acute lymphoblastic leukemia in Phase II. We have industrialized and scalable production with now two own manufacturing sites; one in Europe that we already had but have now extended, and then one in Princeton for the supply in the US that came on stream recently.
And next to all the late stage and manufacturing work we have, we continue to work on leveraging our platform with different preclinical programs that we'll briefly touch upon.
Going to the next slide, Slide 5, you see the pipeline summarized the overview both clinical and preclinical. The half of it is taken by our lead program, eryaspase, which is the Asparaginase in red cells and you'll see again it here, the Phase III in pancreatic -- the pancreatic ductal adenocarcinoma, PDAC in second line studies called TRYbeCA 1 and you will hear that throughout the call, also, I think.
Then the Phase II in triple-negative breast cancer in first line TRYbeCA 2. The second line ALL study Phase II is the NOPHO study, it's an IST and the NOPHO stands for the Nordic Society of Pediatric Haematology and Oncology. So it's them who are the -- it's an investigator sponsored
Chief Executive Officer
Chief Financial Officer & Chief Operating Officer
Chief Medical Officer
We are pleased that you like our content! Sign Up now to access premium content for free, a very limited time offer.
Welcome! Create your account
You are successfully registered!
An activation link has been sent to your mail. Please activate and login.